An Update on the Management of Relapsed and Primary Refractory Hodgkin's Disease

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90% of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3%; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalSeminars in Oncology
Volume31
Issue number2 SUPPL. 4
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Hodgkin Disease
Combined Modality Therapy
Stem Cell Transplantation
Therapeutics
Disease-Free Survival
Blood Cells
Stem Cells
Transplants
Mortality

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

An Update on the Management of Relapsed and Primary Refractory Hodgkin's Disease. / Moskowitz, Craig.

In: Seminars in Oncology, Vol. 31, No. 2 SUPPL. 4, 01.01.2004, p. 54-59.

Research output: Contribution to journalArticle

@article{25e2e1f552cf457baabd2c033d88ee59,
title = "An Update on the Management of Relapsed and Primary Refractory Hodgkin's Disease",
abstract = "With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90{\%} of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3{\%}; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting.",
author = "Craig Moskowitz",
year = "2004",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2004.02.016",
language = "English (US)",
volume = "31",
pages = "54--59",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - An Update on the Management of Relapsed and Primary Refractory Hodgkin's Disease

AU - Moskowitz, Craig

PY - 2004/1/1

Y1 - 2004/1/1

N2 - With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90% of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3%; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting.

AB - With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90% of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3%; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting.

UR - http://www.scopus.com/inward/record.url?scp=2342665691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342665691&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.02.016

DO - 10.1053/j.seminoncol.2004.02.016

M3 - Article

C2 - 15124135

AN - SCOPUS:2342665691

VL - 31

SP - 54

EP - 59

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -